1.

Baseline characteristics.

2.

Baseline characteristics.

3.

Baseline characteristics.

1.

Multimodal analgesia strategies hip surgery.

2.

Multimodal analgesia strategies hip surgery.

3.

Multimodal analgesia strategies hip surgery.

1.

Multimodal analgesia strategies knee surgery.

2.

Multimodal analgesia strategies knee surgery.

3.

Multimodal analgesia strategies knee surgery.

1.

Postoperative pain and side effects.

2.

Postoperative pain and side effects.

3.

Postoperative pain and side effects.

1.

Multivariate logistic regression analysis.

2.

Multivariate logistic regression analysis.

3.

Multivariate logistic regression analysis.

1.

Fig 6 -

2.

Fig 6 -

3.

Fig 6 -

4.

Fig 6 -

5.

Fig 6 -

6.

Fig 6 -

7.

Fig 6 -

8.

Fig 6 -

9.

Fig 6 -

1.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

2.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

3.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

4.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

5.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

6.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

7.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

8.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

9.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

1.

S2 Fig -

2.

S2 Fig -

3.

S2 Fig -

4.

S2 Fig -

5.

S2 Fig -

6.

S2 Fig -

7.

S2 Fig -

8.

S2 Fig -

9.

S2 Fig -

1.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

2.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

3.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

4.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

5.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

6.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

7.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

8.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

9.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

1.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

2.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

3.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

4.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

5.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

6.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

7.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

8.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

9.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.